Application of Esculentoside A in preparing drugs for controlling hepatic fibrosis or cirrhosis

Abstract

The invention which belongs to the technical field of medicine relates to a new use of Esculentoside A in preparing drugs for controlling hepatic fibrosis or cirrhosis. Pharmacological experiments show that: Esculentoside A allows the generation of collagen in hepatic tissues to be substantially inhibited, the fibrosis degree to be reduced and the control effect on hepatic fibrosis and cirrhosis to be fine, so Esculentoside A can be used to prepare the drugs for controlling hepatic fibrosis or cirrhosis. The invention provides a new drug resource for controlling hepatic fibrosis or cirrhosis.

Description

technical field [0001] The invention relates to the technical field of medicine, and is a new application of pokeweed saponin A in the preparation of drugs for preventing and treating liver fibrosis or liver cirrhosis. Background technique [0002] Phytolacca acinsa, a traditional Chinese medicine, has a long history of application and has been included in previous Chinese Pharmacopoeias. Phytolacca is bitter and cold in nature, and returns to the lung, spleen, kidney, and large intestine channels. Chinese medicine believes that it has the effect of dispelling water, reducing swelling, detoxifying and dispelling stagnation. Over the years, more than 30 pokeweed saponins have been isolated and identified, 18 of which are new compounds. [0003] Esculentoside A (Esculentoside A, EsA) is one of the main active ingredients in pokeweed saponin, and its chemical structure is as follows: [0004] [0005] Pokeweed saponin A is a good COX-II inhibitor, which has the effect of ...

AI Technical Summary

Problems solved by technology

[0006] But so far there is no report about pokeweed saponin A having the activity of preventing and treating liver fibrosis or liver cirrhosis

Images